The short answer
SEER reports a 63.7% five-year relative survival rate for multiple myeloma overall. Because myeloma is a cancer of bone marrow cells already present throughout the body, almost all cases are coded distant stage at diagnosis, and that word does not mean here what it means for a solid tumour. Newer drug combinations have meaningfully improved outcomes.
A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.
For multiple myeloma, the five-year relative survival rate for everyone combined, diagnosed 2016–2022, was 63.7%.
SEER's localized/regional/distant categories do not fit myeloma. About 96% of cases are coded distant simply because marrow is everywhere, so 'distant' here does not mean what it means for a solid tumour.
Myeloma specialists typically use a myeloma-specific staging system (R-ISS) rather than the localized/regional/distant categories.
Choose how you want to understand this
The full explanation.
Before you look at the numbers
Three things are true about the numbers below. Please read all three before you look at a single multiple myeloma percentage.
First, a "5-year relative survival rate" for multiple myeloma describes a large group of people. Those people were diagnosed with multiple myeloma years ago. It is not a prediction about you. Everyone's multiple myeloma, body, and treatment plan are different.
Second, this data lags behind today's care. These figures reflect people diagnosed between 2016 and 2022. New drug combinations for multiple myeloma have continued to improve outcomes since then, including some approved quite recently. So multiple myeloma treatment today may already work better than these numbers suggest.
Third, an all-stages multiple myeloma number blends two very different groups. It mixes people whose myeloma was found early with people whose myeloma was already widespread. For multiple myeloma, the stage-specific numbers below beat one blended average. And "5-year" is just a measuring window, not a multiple myeloma milestone. It is not a life expectancy for anyone with multiple myeloma. It is not a deadline either.
The SEER numbers for multiple myeloma
SEER's most recent report covers people diagnosed between 2016 and 2022 with multiple myeloma. Myeloma is a cancer of plasma cells in the bone marrow. Across every stage combined, the five-year relative survival rate was 63.7%. New treatment combinations have greatly improved myeloma outcomes over the past two decades.
Myeloma cells travel through the bone marrow and bloodstream from the start. So about 96% of myeloma is classified as distant stage. The 'localized' and 'regional' categories apply to only a small share of cases. They do not carry the same meaning here that they do for solid tumors.
| Stage at diagnosis | 5-year relative survival |
|---|---|
| Localized (a small share of cases) | 82.1% |
| Regional (a small share of cases) | 80.7% |
| Distant (about 96% of cases) | 63.0% |
The first row covers so few people that it tells you little, and the label on the last row is a coding convention rather than a description of spread. Do not read this table as showing that catching myeloma early lifts survival by twenty points. | Unknown/unstaged | 69.0% |
What "relative survival" actually means
Relative survival compares two groups. One group has multiple myeloma. The other group is the same age and sex, but has no multiple myeloma. Say the rate is 100%. That would mean the multiple myeloma group was as likely to reach 5 years as the other. It is not the share of people who are free of multiple myeloma. It is not the share of people who die from multiple myeloma itself.
Localized, regional and distant staging does not fit myeloma well. So doctors typically use a different system, the Revised International Staging System (R-ISS). It combines blood test results with information about the tumor's genetics. Certain genetic (cytogenetic) changes in the myeloma cells are linked to a higher risk of the disease progressing quickly. They can also affect treatment choices.
What actually changes your outlook
A statistic describes a group. Your outlook depends on things specific to you.
- Stage — how far the multiple myeloma has spread, as shown in the table above.
- Grade — how odd the multiple myeloma cells look, and how fast they tend to grow.
- R-ISS stage — a myeloma-specific staging system that combines blood tests and tumor genetics. It tells you more than SEER's general stage categories.
- Cytogenetic (genetic) risk features — certain genetic changes in myeloma cells are linked to higher-risk disease.
- How your multiple myeloma responds — early scans and labs often say more than the first numbers.
- Your overall health — other health problems, age, and fitness shape multiple myeloma treatment and recovery.
- Access to care — a quick multiple myeloma diagnosis, specialist care, and finishing treatment all matter.
Questions for your care team
- Which SEER stage describes my multiple myeloma, and what is its five-year number?
- Which biomarkers or molecular tests matter in multiple myeloma, and were they run on my sample?
- How do my age and overall health change these multiple myeloma statistics for me?
- Are there newer multiple myeloma treatments available now that this data doesn't reflect yet?
- Beyond the general multiple myeloma statistics, what does my team expect in my case?
- Where can I find support for how it feels to hear these multiple myeloma numbers?
- What is my R-ISS stage and cytogenetic risk category, and how do they affect my treatment plan?
If these numbers are hard to sit with
Multiple myeloma numbers can leave you scared, numb, or overwhelmed. That is normal. It does not mean you are handling a multiple myeloma diagnosis the wrong way. Many people take these multiple myeloma numbers in slowly, or with someone in the room. Others skip the numbers until they feel ready. Cancer Anxiety and Uncertainty covers the fear these multiple myeloma numbers can stir up. It is also worth telling your multiple myeloma team how much detail you want, and when.
Sources
Words to know
Tap any term to see what it means.
Common questions
What does 63.7% five-year relative survival mean for multiple myeloma?
It means that, on average, people diagnosed with multiple myeloma between 2016 and 2022 were about 63.7% as likely to be alive 5 years later as people of the same age and sex without multiple myeloma. It blends every stage together, from early to advanced.
Why is the stage-specific number so different from the overall number?
The overall number blends everyone together, and SEER's stage categories do not split myeloma up in a useful way: nearly all cases are coded distant. What separates one person's outlook from another's here is the R-ISS or R2-ISS stage, built from blood tests and the genetics of the myeloma cells, plus how the disease responds to the first treatment.
Does this number predict what will happen to me?
No. This is a statistic about a large group of people, not a prediction about you. Your age, overall health, tumor biology, and how your multiple myeloma responds to treatment all shape your individual outlook in ways a group statistic cannot capture.
Is this the most current data available?
It is the most recent data SEER has published, but it still reflects people diagnosed in 2016–2022. Treatments keep changing, so people diagnosed today may do better than these numbers suggest.
Why is 'distant stage' myeloma survival (63.0%) so much higher than distant-stage survival for cancers like lung or pancreatic cancer?
Because 'distant' means something different for myeloma. Multiple myeloma starts in bone marrow, which is already spread throughout the body, so almost every case is technically 'distant' by SEER's definition from the moment it's diagnosed. That is very different from a solid tumor spreading from one organ to distant ones, and it's why myeloma specialists rely on the R-ISS system instead.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-19Next planned review: 2027-08-03
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share